ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0851

Lupus Nephritis Flares Linked to Platelet Activation During Gut Pathobiont Blooms

Abhimanyu Amarnani1, Doua Azzouz2, MacIntosh Cornwell3, David Mieles3, Peter Izmirly4, Jill Buyon5, Kelly Ruggles6 and Gregg Silverman5, 1NYU Langone Medical Center, New York, NY, 2NYU Langone Health ( School of medicine), New York, NY, 3New York University, New York, NY, 4New York University School of Medicine, New York, NY, 5NYU Grossman School of Medicine, New York, NY, 6NYU Langone, New York, NY

Meeting: ACR Convergence 2023

Keywords: Lupus nephritis, microbiome, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 12, 2023

Title: Abstracts: SLE – Diagnosis, Manifestations, & Outcomes I: Biomarkers

Session Type: Abstract Session

Session Time: 4:00PM-5:30PM

Background/Purpose: Systemic lupus erythematosus (SLE) is associated with gut microbiota dysbiosis, and community imbalance can coincide with flares of Lupus nephritis (LN). Herein, we sought to understand the blood cell gene expression patterns and antibody responses to a gut pathobiont in longitudinal assessments of SLE patients with LN and concurrent gut colonization blooms of Blautia (Ruminococcus) gnavus (RG).

Methods: In a well-characterized SLE cohort, we performed bulk RNA-seq from whole-blood PAXGene tubes. Our cohort consisted of 24 female subjects (8 controls, 8 with non-renal SLE, 4 LN without RG blooms, and 4 LN concurrent with RG blooms) with longitudinal assessment of whole-blood RNA sequencing, lupus activity, and serum anti-RG lipoglycan antibody levels. After quality control and filtering, gene expression profiles were analyzed. Serum levels of the platelet factors, P-selectin and platelet factor 4 (PF4), were assessed by ELISA.

Results: Differential expression and unsupervised clustering analysis revealed distinct gene expression patterns between LN patient without and with RG gut blooms (372 differentially expressed genes; p< 0.01. Gene set enrichment analysis of the differentially expressed genes revealed significant enrichment for “platelet activation”, “platelet alpha granule” and “platelet degranulation” pathways (Figure 1A, FDR < 0.001). Gene expression levels in SLE samples were compared to controls (Figure 1B). As platelet degranulation was found to be upregulated in a subset of LN patients with RG blooms, we interrogated serum levels of P-selectin/CD62P, a protein produced by activated platelets affecting leukocyte activation/migration. We found that P-selectin was increased in LN patients with RG blooms. No significant difference was observed in LN patient without RG blooms or non-renal SLE patients (Figure 2A). The gene expression of PF4, a chemokine protein primary secreted by platelets upon activation was found to be higher in LN RG, compared to controls (Figure 1A). Serum P-selectin directly correlated with PF4 levels (p=0.003)(Figure 2B).

Conclusion: Patients with LN and RG gut blooms displayed upregulated expression of genes for platelet activation and degranulation. Gut blooms with the pathobiont RG, known to cause gut leakiness from the gut and induce high serum anti-RG lipoglycan antibodies, are herein associated with increased platelet activation and raised serum P-selectin and PF4. Taken together, our data point to a potential role for platelet activation and thrombo-inflammation in LN pathogenesis.

Supporting image 1

Figure 1. LN patients with RG gut blooms overexpress genes, including for platelet activation. (A) Volcano plot of genes differentially expressed in LN patients with (LN RG) and without RG bloom (LN No Bloom) (Red indicates p<0.01 and log2FC>1 or <_1, and green p<0.01 with Log2FC <1 or >_1). (B) Heatmap illustrates differential gene expression in patients with non-renal SLE (SLE Not LN), LN (LN No Bloom), and RG blooms (LN RG), compared to control samples, for 11 genes that intersect with the “Platelet Activation” pathway.

Supporting image 2

Figure 2. P-selectin levels are increased in patients with LN and RG bloom. (A) P-selectin/CD62-P levels in SLE patients and (B) correlation of P-selectin and PF_4 s in sera of patients with LN and levels of serum RG anti-LG antibodies above level in healthy individuals (p=0.003). *indicates p<0.05, non-parametric Mann-Whitney U analysis of LN RG vs. Control. Based on commercial ELISA of serum (P-selectin 1:400, PF4 1:20, ng/mL).


Disclosures: A. Amarnani: None; D. Azzouz: None; M. Cornwell: None; D. Mieles: None; P. Izmirly: None; J. Buyon: Bristol-Myers Squibb(BMS), 2, GlaxoSmithKlein(GSK), 2, Related Sciences, 1; K. Ruggles: None; G. Silverman: None.

To cite this abstract in AMA style:

Amarnani A, Azzouz D, Cornwell M, Mieles D, Izmirly P, Buyon J, Ruggles K, Silverman G. Lupus Nephritis Flares Linked to Platelet Activation During Gut Pathobiont Blooms [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/lupus-nephritis-flares-linked-to-platelet-activation-during-gut-pathobiont-blooms/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/lupus-nephritis-flares-linked-to-platelet-activation-during-gut-pathobiont-blooms/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology